Heptares Therapeutics announced that an operating company of Shire plc has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the reg ... more
To use all functions of this page, please activate cookies in your browser.
